Please wait...
99
195
Offers Claimed: 41
Downloaded Today: 68
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Note: This document contains side effect information about progesterone. Some of the dosage forms listed on this page may not apply to the brand name Endometrin.
For the ConsumerApplies to progesterone: oral capsule, oral capsule liquid filled
Oral route (Capsule, Liquid Filled)
Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) have been reported with estrogen plus progestin therapy. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration possible.
Along with its needed effects, progesterone (the active ingredient contained in Endometrin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking progesterone:
More common
Less common
Incidence not known
Some side effects of progesterone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Incidence not known
For Healthcare Professionals
Applies to progesterone: compounding powder, intramuscular solution, oral capsule, topical cream, vaginal gel, vaginal insert, vaginal suppository
GenitourinaryVery common (10% or more): Breast enlargement (40%), breast tenderness (27%), perineal pain female (17%), breast pain (16%), nocturia (13%), urinary problems (11%), vaginal discharge (11%)
Common (1% to 10%): Ovarian hyperstimulation syndrome, breast pain, vaginal dryness, pruritus genital, uterine spasm, vaginal bleeding, altered periods, amenorrhea, intercurrent bleeding
Uncommon (0.1% to 1%): Vulvovaginal disorders, vaginal mycosis, breast disorders, pollakiuria, incontinence, ovarian enlargement, pelvic pain, vulvovaginal pruritus, galactorrhea
Frequency not reported: Vaginal irritation, vaginal burning, vaginal discomfort, fatty discharge, changes in cervical erosion and secretions
Postmarketing reports: Hypospadia, intra-uterine death, menorrhagia, menstrual disorder, metrorrhagia, ovarian cyst, spontaneous abortion
Nervous systemVery common (10% or more): Headache (31%), somnolence (27%), dizziness (24%)
Uncommon (0.1% to 1%): Dysgeusia
Frequency not reported: Extreme dizziness and/or drowsiness, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion, disorientation, insomnia
Postmarketing reports: Convulsion, depressed consciousness, dysarthria, loss of consciousness, paresthesia, sedation, stupor, syncope (with and without hypotension), transient ischemic attack, abnormal gait, difficulty walking
PsychiatricVery common (10% or more): Emotional lability (23%), depression (19%), sleep disorder (18%), nervousness (16%), libido decreased (10%)
Common (1% to 10%): Worry
Uncommon (0.1% to 1%): Mood altered
Postmarketing reports: Aggression, depersonalization, disorientation, suicidal ideation
CardiovascularVery common (10% or more): Hot flashes (11%)
Uncommon (0.1% to 1%): Hemorrhage
Rare (less than 0.1%): Thromboembolism or thrombus formation
Postmarketing reports: Circulatory collapse, congenital heart disease (including ventricular septal defect and patent ductus arteriosis), hypertension, hypotension, tachycardia
GastrointestinalVery common (10% or more): Abdominal pain (20%), abdominal bloating (12%)
Common (1% to 10%): Nausea/vomiting, diarrhea, abdominal distension, constipation
Uncommon (0.1% to 1%): Flatulence, gastric dilatation
Postmarketing reports: Acute pancreatitis, dysphagia, swollen tongue, cleft palate
MusculoskeletalVery common (10% or more): Joint pain (20%), cramps NOS (15%), musculoskeletal pain (12%)
Common (1% to 10%): Back pain, arthralgia, myalgia
Postmarketing reports: Cleft lip, muscle cramp
RespiratoryCommon (1% to 10%): Coughing, upper respiratory tract infection
Frequency not reported: Shortness of breath
Postmarketing reports: Choking, dyspnea, asthma, throat tightness
DermatologicCommon (1% to 10%): Night sweats
Uncommon (0.1% to 1%): Pruritus, acne
Very rare (less than 0.01%): Urticaria, chloasma
Frequency not reported: Itching, hirsutism
Postmarketing reports: Alopecia, face edema
OtherVery common (10% or more): Post oocyte retrieval pain (28%), viral infection (12%), hot flashes (11%)
Common (1% to 10%): Fatigue, pain, chest pain, swelling of hands and feet, breast excisional biopsy
Uncommon (0.1% to 1%): Peripheral edema, feeling cold, feeling of body temperature change, discomfort, weight increased
Frequency not reported: Feeling drunk, pyrexia
Postmarketing reports: Feeling abnormal, tinnitus, weight decreased
HepaticCommon (1% to 10%): Cholecystectomy
Uncommon (0.1% to 1%): Cholestatic jaundice
Postmarketing reports: Cholestasis, cholestatic hepatitis, hepatic failure, hepatic necrosis, hepatitis, increased liver function tests (including alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase increases), jaundice
MetabolicCommon (1% to 10%): Hyperglycemia
Postmarketing reports: Blood glucose increased
OncologicCommon (1% to 10%): Breast carcinoma
Uncommon (0.1% to 1%): Rectal neoplasm
Postmarketing reports: Endometrial carcinoma
OcularFrequency not reported: Blurred vision
Postmarketing reports: Diplopia, visual disturbance
HypersensitivityUncommon (0.1% to 1%): Hypersensitivity reactions
Postmarketing reports: Anaphylactic reaction
EndocrineRare (less than 0.1%): Adrenal suppression or insufficiency
LocalFrequency not reported: Injection site reaction
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.
Source: Drugs.com Endometrin (www.drugs.com/endometrin.html).
August 4, 2022
August 4, 2022
August 4, 2022
July 26, 2022
July 26, 2022
July 22, 2022